Bio-Techne (NASDAQ: TECH) reported Q4 EPS of $0.55, in-line with the analyst estimate of $0.55. Revenue for the quarter came in at $301.32 million versus the consensus estimate of $307.61 million.

For earnings history and earnings-related data on Bio-Techne (TECH) click here.